Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 3/20 | 0.39 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | CCND1 | P24385 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26887312 | 0.79 | DAO (0.38) | DAOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL19002596 | 0.78 | DAO (0.61) | KDM4CGLADAO | |
| SCHEMBL7768510 | 0.76 | — | — | |
| SCHEMBL19002599 | 0.75 | KDM4E (0.49) | KDM4CGLADAOCDK4CCND1 | |
| SCHEMBL28286935 | 0.71 | MPO (0.44) | KDM4CGLA | |
| SCHEMBL24445917 | 0.70 | — | — | |
| SCHEMBL7484552 | 0.70 | GLA (0.39) | KDM4CGLAPDK2 | |
| SCHEMBL18711683 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL6618258 | 0.69 | GLA (0.35) | KDM4CGLAHTTPDK2PDK4 | |
| SCHEMBL3392370 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509507-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20050234080-A1 | Mitotic kinesin inhibitors | COLEMAN PAUL J | 2005-10-20 | — | — | US | disclosed |
| EP-1509507-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003099211-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234080-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIFC1 | KDM4C 846/4885GLA 2442/4885DAO 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.